Research ResourceCancer
Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma
- Kristina B. Emdal1,2,*,
- Anna-Kathrine Pedersen1,*,
- Dorte B. Bekker-Jensen1,
- Alicia Lundby1,3,
- Shana Claeys4,
- Katleen De Preter4,
- Frank Speleman4,
- Chiara Francavilla1,5,†,‡, and
- Jesper V. Olsen1,†,‡
- 1Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.
- 2Department of Biological Engineering and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
- 3Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark.
- 4Center for Medical Genetics Ghent, Cancer Research Institute Ghent, De Pintelaan 185, 9000 Ghent, Belgium.
- 5Division of Molecular and Cellular Functions, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.
- ↵‡Corresponding author. Email: chiara.francavilla{at}manchester.ac.uk (C.F.); jesper.olsen{at}cpr.ku.dk (J.V.O.)
See allHide authors and affiliations
Science Signaling 20 Nov 2018:
Vol. 11, Issue 557, eaap9752
DOI: 10.1126/scisignal.aap9752
